Multiple studies support flexible approach to treating actinic keratoses with imiquimod

Article

In early March, the FDA granted marketing approval for use of imiquimod cream in the treatment of nonhyperkeratotic, nonhypertrophic AKs on the scalp or face in immunocompetent individuals.

Related Videos
Related Content

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023
© 2023 MJH Life Sciences

All rights reserved.